BRCA2 reversion mutation confers resistance to olaparib in breast cancer.
Shinya YamamotoKei KawashimaYoshie FujiwaraShoko AdachiKazutaka NaruiChiaki HosakaRina TakahashiSho TsuyukiMakoto SugimoriMiki TanoshimaMahato SasamotoMasanori OshiAkimitsu YamadaChikara KunisakiItaru EndoPublished in: Clinical case reports (2023)
p.Gln3047Ter and p.Gln3047Tyr, with 48.9% and 0.37% allele frequency, respectively. These findings shed light on reversion mutation as a mechanism of resistance to olaparib in breast cancer.
Keyphrases